BNET Industries

Market Cap:$10.7M
Last Fiscal Year Sales:$756.2K
  • Public
  • US
Dow Jones Description

Ceragenix is developing next generation therapies and products based on its two platforms of technologies both of which mimic key components of the innate immune system CeraShield and Skin Barrier Repair Technology (BRT). Our goal is to become a market leader in developing novel and high-impact therapies and medical products for selected markets in infectious disease and dermatology. The Company seeks to enjoy early revenue opportunities from its first FDA cleared skin Barrier Repair Therapy product, EpiCeram , and will use this cash flow to focus on development of our CeraShield antimicrobial technology for medical devices which is designed to reduce the morbidity, mortality and healthcare costs associated with hospital acquired infections associated with indwelling medical devices. Headquartered in Denver, Colorado, Ceragenix Pharmaceuticals, Inc. was launched as a public company in 2005 after completing the acquisition of Osmotics Pharma, Inc. The Company has maintained a lean infrastructure, leveraging contract research partners and academic labs for initial proof of concept studies.

Chief Executive Officer, Chairman and Director
Steven Porter
Contact Information

1444 Wazee Street

Suite 210

Denver, Colorado 80202

ceragenix.com

7209466440

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Ceragenix Pharmaceuticals, Inc. (CGXP.OB) and Megapharm Enter Into Distribution and Supply Agreement for EpiCeram

    7/27/09 - Joint Venture / Alliance - View Story

  • Ceragenix and Nobel Biocare Enter into Option to License Agreement for Antimicrobial Technology

    7/09/09 - Joint Venture / Alliance - View Story

News & Analysis

ceragenix pharmaceuticals inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Jeff Sperber Director, Chief Financial Officer
Peter Elias Chief Scientific Officer
Carl Genberg Senior Vice President
Russell L. Allen Vice President of Corporate Development
Donald Y M Leung Professor and Head of Pediatric

Board of Directors

Name (plus bio) Position
Steven Porter Chief Executive Officer, Chairman and Director
Cheryl A. Hoffman-Bray Director and Chair of Audit Committee
Philippe J. Gastone Director and Chair of Compensation Committee
Michael S Niederman Prof of Medicine and Chairman of The Department of Medicine at The State University of New York
Sean P Gorman Head of School and Chair
Alberto J Bautista Board of Directors
Henry F Chambers Board of Directors
Michael J Rybak Board of Directors
Michel Darnaud Board of Directors
Richard Gallo Board of Directors
Tomas Ganz Board of Directors

Steven S. Porter has served as the Company s Chief Executive Officer and Chairman since May 2005. Prior to joining us, he served as Chief Executive Officer and Chairman of the Board of Osmotics from its inception in August 1993 until May 2005. He served as a director of Osmotics Corporation through December 2007. He has served as Chief Executive Officer and Chairman of Ceragenix Corporation since February 2002. In January 1986, Mr. Porter and two other individuals founded GDP Technologies, Inc. (GDP), a medical imaging company, completing major strategic partnerships with Olympus Optical, Japan, GE Medical and Bruel & Kjaer, Denmark. From that time until August 1993, Mr. Porter served as Executive Vice President of GDP. Prior to 1986, Mr. Porter was the National Sales Manager for Protronyx Research, Inc., a large scale scientific computer systems company, working with the United States Department of Energy, United States Department of Defense, Boeing and the National Security Agency. Mr. Porter has a Bachelor of Arts degree in Economics from UCLA.

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Chief Executive Officer, Chairman and Director Current
Osmotics Corporation Chief Executive Officer Former
Osmotics Corporation Chairman of the Board Former
Osmotics Corporation Director Former
University of California, Los Angeles Bachelor of Arts Degree In Economics Former

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Director, Chief Financial Officer Current
Osmotics Corporation Chief Financial Officer Former
Telecommunications Ltd Business Unit Controller Former

Dr. Peter Elias has served as Chief Scientific Officer since May 2005. Dr. Elias has served as Ceragenix Corporation s Chief Scientific Officer since May 2004. From 1975 through 2003, Dr. Elias was a Professor of Dermatology at the University of California, San Francisco where he most recently served as the Vice Chairman of the Department of Dermatology. Between his tenure at the University of California and joining Ceragenix Corporation, Dr. Elias worked as an independent consultant and advisor. Dr. Elias has published over 500 papers and has received numerous honors, awards and professional appointments as a result of his expertise in the field of dermatology. Dr. Elias received his B.A. from Stanford University and his M.D. and M.S. from the University of California, San Francisco.

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Chief Scientific Officer Current
Osmotics Corporation Current
Ceragenix Pharmaceuticals, Inc. Board of Directors Current
California Academy of Sciences Fellow Current
University of California Advisor Former
University of California, San Francisco Professor Former
Veterans Administration Medical Center Former
University of California, San Francisco Chairman Former
University of California, San Francisco Vice-Chairman Former
University of California, San Francisco M.D. Former
Stanford University B.A. Former

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Senior Vice President Current
Ceragenix Pharmaceuticals, Inc. President Former
Osmotics Corporation Senior Vice President, Research and Development Former
The Ohio State University College of Law Juris Doctorate Degree Former

Organization Position Status
Ibex Technologies Vice President Current
Ceragenix Pharmaceuticals, Inc. Vice President of Corporate Development Current
Ibex Technologies Board of Directors Current
Amherst College B.A. Former

Cheryl A. Hoffman-Bray was elected as a director of the Company in June 2005. Since August 2006, Ms. Hoffman-Bray has served as the Chief Financial Officer of the Education Development Center, Inc., a non-profit organization that manages projects addressing world wide education and health care needs. From October 2004 through March 2006, she served as the Senior Advisor to the Executive Dean of Harvard University. She served as the Dean of Finance and Chief Financial Officer of Harvard s Faculty of Arts and Sciences from March 2000 until October 2004. Ms. Hoffman Bray served as Chief Financial Officer and Senior Vice President of Finance at the Beth Israel Deaconess Medical Center from May 1998 to May 1999. From October 1996 until May 1998, she served as the Medical Center s Vice President of Finance. From January 1995 to October 1996, Ms. Hoffman Bray served as the Senior Vice President and Chief Financial Officer of the New England Deaconess Hospital in Boston, Massachusetts. From June 1984 to December 1994, she worked for Albany Memorial Health Systems, Inc., serving as their Vice President and Chief Financial Officer from July 1989 until December 1994 and as the Controller and Director of Fiscal Services from June 1984 until July 1989. From 1980 until May 1984, she was employed by Coopers & Lybrand. Ms. Hoffman Bray graduated from the State University of New York at Albany 1979 with a Bachelor of Science in Accounting and received her Master of Science from the University in 1980. Ms. Hoffman Bray is a member of the Boston Club and a director of the Harvard Cooperative Society.

Organization Position Status
Education Development Center Inc. Chief Financial Officer Current
Ceragenix Pharmaceuticals, Inc. Director and Chair of Audit Committee Current
Harvard University Senior Advisor Current
The Boston Club Board of Directors Current
Ceragenix Pharmaceuticals, Inc. Director Current
Harvard Cooperative Society Inc. Director Current
The Boston Club Member Current
Beth Israel Deaconess Medical Center Chief Financial Officer Former
New England Deaconess Hospital Senior Vice President and Chief Financial Officer Former
Beth Israel Deaconess Medical Center Senior Vice President of Finance Former
University Corp. Master of Science Former
The State University of New York Bachelor of Science Former
State University of New York at Albany Bachelor of Science In Accounting Former

Organization Position Status
Huttig Building Products, Inc. Senior Vice President, Cemex Current
Ceragenix Pharmaceuticals, Inc. Director and Chair of Compensation Committee Current
Timber Treatment Technologies, LLC Current
Ceragenix Pharmaceuticals, Inc. Board of Directors Current
Huttig Building Products, Inc. Director Current
Cemex, Inc. Senior Vice President Former
Booz Allen Hamilton, Inc. Former
The Boston Consulting Group, Inc. Former
INSEAD MBA Former

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Professor and Head of Pediatric Current
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Prof of Medicine and Chairman of The Department of Medicine at The State University of New York Current
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Head of School and Chair Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current
Ajb Consulting Ltd Founder Former
MIT Sloan School of Management M.S. In Management Former
Ajb Consulting Ltd Principal Consultant Former
University Corp. M.S. In Management Former
MIT Sloan School of Management M.S. In Management Former
University Corp. B.S. In Industrial Engineering Former

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current
Baxter International Inc. Former
Diagnostica Stago, Inc. General Manager Former

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Organization Position Status
Ceragenix Pharmaceuticals, Inc. Board of Directors Current

Executive News

  • Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM)...

    Forbes.com - 9/01/09 - View Story

  • Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield Antimicrobial Coating Application

    Business Wire - 9/01/09 - View Story

  • Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield„ Antimicrobial Coating Application

    Business Wire - 9/01/09 - View Story

  • Ceragenix Completes Long-Term Antimicrobial Efficacy Test on Treated Silicone Medical Device

    Business Wire - 8/13/09 - View Story

advertisement
     CGXP $0.59 0.00 (0.00% )
Average Volume 6,778
Shares Outstanding 18.18M
Market Cap 10.7M
Year High 0.9
Year Low 0.16
Earnings Per Share -0.47
P/E Ratio -1.26
Dividend N/A
Yield N/A
advertisement
Click Here